We are Minomic
Developer of novel cancer diagnosticsWe have developed MiCheck® Prostate for prostate cancer
Trials
A series of clinical trials have shown MiCheck® Prostate yields more accurate results than existing blood tests for aggressive prostate cancer.
Diagnosis
MiCheck® Prostate fills a major need in prostate cancer diagnostics to follow on a reported elevated PSA level. It allows better triage of patients by differentiating aggressive cancer from non-aggressive or no cancer before an invasive and expensive biopsy.
Validation
We have formed a partnership with Cirrus Dx (US) to offer MiCheck® Prostate as a Laboratory Developed Test available through the Clinical Laboratory Improvements Amendment (CLIA) Act.
Distribution
We have partnered with Cirrus Dx to offer MiCheck® Prostate as a Laboratory Developed Test in your area.
Company Pipeline Development Summary
Company Background
We are based in Sydney, adjacent to one of Australia’s leading universities, Macquarie University, and the Macquarie University Hospital, one of our key collaborators.
Our reach is global, through partnerships with universities, research institutes, and companies.
Our experience is backed up by independent experts in oncology, awards of multiple research grants, a major innovation prize, and investment backing of over A$27 million to date.
Extensive intellectual property
Minomic owns an extensive patent estate protecting our distinctive technology. All the intellectual property relevant to our technology is owned by us.
Our investors and funding support
Minomic is an unlisted public company.
Apart from equity investment, other sources of funding include:
- an Australian Government Accelerating Commercialisation grant to help validate MiCheck® Prostate and support our rollout;
- Australian Government R&D Tax Incentives;
- a National Health and Medical Research Council Development Grant with QUT;
- ARC Hub award.
Contact us if you are interested in investing in the future of Minomic International.